Mesenchymal Stem Cells as Anti-Inflammatory Agents in Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Cells · 2025
DOI: 10.3390/cells14171313 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cells, 2025. Verfasst von Lukman Pura und 6 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral Study Program of Medical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung 40132, Indonesia. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Mesenchymal Stem Cells, Mesenchymal Stem Cell Transplantation, Anti-Inflammatory Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Directorate of Research, Downstream and Community Service (DRHPM) of Universitas Padjadjaran.
Abstract (Originalsprache)
Background
Chronic kidney disease (CKD) is largely driven by inflammation. Mesenchymal stem cells (MSCs) show therapeutic potential; however, their efficacy across CKD etiologies remains unclear.
Methods
Comprehensive searches were conducted in PubMed, Cochrane, ScienceDirect, Scopus and Google Scholar. Effect sizes for inflammation and renal function outcomes were meta-analyzed.
Results
Of 2514 studies screened, 52 met inclusion criteria (49 animal studies, 3 randomized controlled trials). In animal models, MSCs significantly reduced interleukin-6 (mean difference [MD] = −155.80; 95% CI: −249.10, −62.51; p = 0.001) and tumor necrosis factor-α (TNF-α) (MD = −35.53; 95% CI: −52.75, −18.30; p < 0.0001). In patients, TNF-α reduction was not significant (MD = −0.74; 95% CI: −2.20, 0.73; p = 0.32). Serum creatinine decreased in animals (MD = −0.38; 95% CI: −0.46, −0.29; p < 0.00001), but not in patients (MD = −0.59; 95% CI: −1.92, 0.74; p = 0.39). Blood urea nitrogen decreased in animals (MD = −19.27; 95% CI: −23.50, −15.04; p < 0.00001), and glomerular filtration rate improved (standardized MD = 1.83; 95% CI: 0.51, 3.15; p = 0.007), with no change in patients.
Conclusion
MSCs improve inflammation and renal function in CKD animal models; however, evidence in patients remains inconclusive.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Doctoral Study Program of Medical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung 40132, Indonesia.
- Dr. H. Abdul Moeloek Regional General Hospital, Bandar Lampung 35112, Indonesia.
- Master Study Program of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung 40132, Indonesia.
- Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital, Bandung 40161, Indonesia.
- Department of Neurosurgery and Stem Cell Working Group, Faculty of Medicine, Universitas Padjadjaran/Padjadjaran University Hospital, Jatinangor 45363, Indonesia.
Förderung
- Directorate of Research, Downstream and Community Service (DRHPM) of Universitas Padjadjaran
Zitieren
APA
Pura, L., Putri, R. D., Prahmana, M. A., Wijaya, M. P., Bandiara, R., Faried, A., & Supriyadi, R. (2025). Mesenchymal Stem Cells as Anti-Inflammatory Agents in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Cells. https://doi.org/10.3390/cells14171313
Vancouver
Pura L, Putri RD, Prahmana MA, Wijaya MP, Bandiara R, Faried A, et al. Mesenchymal Stem Cells as Anti-Inflammatory Agents in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Cells. 2025. doi:10.3390/cells14171313
BibTeX
@article{Pura2025,
author = {Pura, Lukman and Putri, Raeni Dwi and Prahmana, Muh Arya and Wijaya, Muhammad Palar and Bandiara, Ria and Faried, Ahmad and Supriyadi, Rudi},
title = {Mesenchymal Stem Cells as Anti-Inflammatory Agents in Chronic Kidney Disease: A Systematic Review and Meta-Analysis},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14171313}
}
EUVIMED